List of Excipients in Branded Drug DEFERIPRONE

Generic Drugs Containing DEFERIPRONE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	deferiprone	0054-0576	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	deferiprone	0054-0576	CROSPOVIDONE
Hikma Pharmaceuticals USA Inc	deferiprone	0054-0576	HYPROMELLOSE

What are the Most Frequently-Used Excipients in DEFERIPRONE?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE K25-31
4	CROSPOVIDONE

Deferiprone Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Deferiprone is a mature oral iron chelator with limited active-ingredient patent protection and continuing commercial potential in formulations, pediatric delivery, adherence products, and geographically tailored generics. The highest-value excipient opportunities are taste masking, oral-solution stability, dose flexibility, tablet swallowability, and differentiation of twice-daily or pediatric presentations. Excipients cannot materially reduce deferiprone’s principal safety risks, particularly neutropenia and agranulocytosis, so commercial claims should focus on usability, dosing convenience, stability, and patient adherence rather than clinical safety improvement.

What is the FDA status of deferiprone?

The U.S. Food and Drug Administration approved Ferriprox, deferiprone, for patients with transfusional iron overload caused by thalassemia syndromes when chelation therapy is inadequate. The product is marketed by Chiesi USA, Inc. and is available in tablets and oral solution presentations.[1]

Product	Dosage form	Strength	Primary commercial use
Ferriprox tablets	Immediate-release tablet	500 mg and 1,000 mg	Adult and pediatric oral chelation
Ferriprox oral solution	Oral solution	100 mg/mL	Pediatric use, dose flexibility, swallowing limitations
Generic deferiprone	Tablets and, depending on market, oral liquid	Market-specific	Cost-sensitive substitution and tender markets

The product carries a boxed warning for agranulocytosis and neutropenia. Prescribing information requires regular absolute neutrophil count monitoring. This warning is central to regulatory positioning and limits the commercial value of excipient claims suggesting improved hematologic safety.[1]

Ferriprox is a small-molecule genericizable product rather than a biologic. Biosimilar regulation does not apply. Competition is governed by abbreviated new drug application pathways, local generic rules, product quality, supply reliability, and patent or exclusivity status.

What excipients are used in deferiprone products?

The reference product uses conventional oral solid and liquid excipient systems. Exact compositions vary by presentation, manufacturing site, country, and label revision. FDA-approved labeling identifies the inactive ingredients for the marketed presentations and should control any product-development comparison.[1]

Tablet excipient strategy

Deferiprone tablets generally rely on a conventional immediate-release platform containing:

• A diluent or compression aid, such as microcrystalline cellulose
• A disintegrant
• A glidant, such as colloidal silicon dioxide
• A lubricant, such as magnesium stearate
• Film-coating materials
• Colorants or opacifiers, where applicable

The active ingredient is a small, relatively low-dose molecule compared with many specialty drugs. The primary tablet-development challenge is therefore not payload capacity. It is achieving consistent content uniformity, rapid disintegration, acceptable mechanical strength, and a swallowable dosage form at clinically relevant daily doses.

Deferiprone dosing can require multiple tablets per administration. A 1,000 mg strength reduces tablet burden compared with 500 mg tablets but increases tablet dimensions and swallowing difficulty. A manufacturer can pursue differentiated tablet geometry, scored tablets, multilayer compression, or modified packaging without necessarily creating a strong patent position. The commercial value is more likely to arise from patient preference and adherence data than from the excipient composition alone.

Oral-solution excipient strategy

The oral solution is the more important formulation opportunity. A liquid product must address:

• Deferiprone solubility and concentration stability
• Metallic, bitter, or otherwise unpleasant taste
• Chemical stability during the labeled shelf life
• Microbial preservation
• Dose-measurement accuracy
• Container compatibility
• Pediatric acceptability

Potential excipient functions include sweeteners, flavors, viscosity modifiers, buffers, preservatives, antioxidants, and chelating or complexing agents. Each excipient requires compatibility testing because deferiprone itself is an iron-binding molecule. Trace metals from raw materials, manufacturing equipment, closures, or water systems can alter product quality and may create assay or impurity concerns.

A liquid formulation should not be designed around taste masking alone. High viscosity can improve mouthfeel but may reduce dose-measurement accuracy and increase residue in oral syringes. Strong flavor systems can create pediatric acceptability issues across age groups. Preservative systems must be evaluated against pH, container adsorption, microbial challenge results, and repeated-use handling.

Which excipient strategies have the greatest commercial value?

Taste masking and pediatric acceptability

Taste masking is the most direct opportunity for differentiation. Deferiprone is administered chronically, often to children or young adults with transfusion-dependent disease. A formulation that reduces bitterness or metallic aftertaste can improve persistence with treatment.

Commercially relevant approaches include:

1. Flavor-screened oral solutions using age-specific profiles.
2. Sweetener systems with reduced aftertaste.
3. Ion-exchange resin complexes or polymeric taste-masking systems.
4. Multiparticulates or coated granules for administration with soft food.
5. Orodispersible or chewable presentations for patients unable to swallow tablets.

The strongest product profile would combine acceptable taste with dose accuracy and chemical stability. A taste-masked formulation that requires substantial reconstitution, refrigeration, or complex administration may have limited practical value.

Dose flexibility

The labeled oral solution concentration provides flexibility for weight-based pediatric dosing and patients transitioning between age groups. A differentiated liquid could improve dose adjustment, particularly where dose changes are frequent or where tablets create a high pill burden.

The opportunity is strongest in markets where:

• Pediatric thalassemia treatment is concentrated in specialist centers.
• Caregivers administer medicines at home.
• Local dosing practices require fine weight-based adjustment.
• Tablet supply is intermittent.
• Reimbursement recognizes a liquid product as medically necessary.

Unit-dose sachets, prefilled oral syringes, or a concentrated formulation may reduce caregiver error. These formats introduce packaging and extractables-and-leachables work but can create defensible device or combination-product positions.

Stability and packaging

Deferiprone liquid products require careful control of oxygen, light, metals, and microbial exposure. Commercially useful stability improvements could include:

• Low-metal-contact manufacturing equipment
• High-barrier bottles
• Light-protective packaging
• Child-resistant closures with easier caregiver handling
• Unit-dose containers
• In-use stability supported by oral-syringe compatibility data

Packaging may provide a stronger practical barrier than a broad excipient patent. A manufacturer that demonstrates longer in-use stability, lower dosing waste, or improved transport robustness can win tenders and hospital contracts even where the active ingredient is fully generic.

What formulation patents could protect deferiprone products?

A conventional tablet containing standard fillers, disintegrants, glidants, and lubricants is unlikely to support a durable composition-of-matter position for a mature generic drug. Patent value is more plausible in the following areas:

Patent target	Potential claim scope	Commercial strength
Taste-masked deferiprone	Drug-resin complex, coated particles, flavor system, or bitterness threshold	Moderate to high if clinically meaningful
Pediatric liquid	Specific concentration, pH, preservative, and stability profile	Moderate
Modified release	Release profile, dosing frequency, pharmacokinetic exposure	High if clinically differentiated
Multiparticulate product	Coated granules, sprinkle formulation, food compatibility	Moderate
Packaging system	Container, closure, dosing syringe, light or oxygen barrier	Low to moderate
Manufacturing process	Impurity control, metal control, crystallization, or scale-up process	Moderate
Combination product	Deferiprone with another chelator or adherence technology	High but development-intensive

Patent claims should be anchored to measurable technical effects. Examples include improved chemical stability, reduced degradation products, defined dissolution performance, taste scores, reduced dose variability, or improved in-use shelf life. A formulation patent based only on substituting one conventional excipient for another is vulnerable to obviousness and design-around attacks.

When does deferiprone lose exclusivity?

Deferiprone’s core active-ingredient protection is mature, and the product is exposed to generic competition in jurisdictions where regulatory approvals are available. The relevant U.S. barriers are not limited to patent expiry. FDA regulatory exclusivity, listed patents, pediatric extensions, and litigation outcomes must be reviewed in the current Orange Book and FDA approval records.[2]

Orange Book and Paragraph IV exposure

For an ANDA applicant, the principal routes are:

• Paragraph I certification if no relevant patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification with a delayed launch after patent expiry.
• Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.

Because deferiprone is an older small molecule, the main competitive risk is likely to come from formulation, method-of-use, and product-specific patents rather than from basic active-ingredient claims. A generic applicant should map the Orange Book to:

• Tablet strengths
• Oral-solution presentation
• Method-of-use listings
• Pediatric indications
• Any later-added formulation patents
• Regulatory exclusivity dates

A formal launch assessment requires the current FDA Orange Book, approved labeling, and litigation docket because listed patents and procedural status can change.

What patent litigation affects deferiprone?

The principal litigation risk for a deferiprone entrant is not typically a biosimilar dispute. It is an ANDA patent case involving the reference sponsor or a later formulation owner. Potential disputes may concern:

• Oral-solution composition
• Stability-enhancing excipients
• Dose regimens
• Treatment of transfusional iron overload
• Use in pediatric populations
• Manufacturing or impurity-control processes

An ANDA entrant can reduce litigation exposure by developing a tablet-only product, selecting a different liquid composition, or using a non-infringing method-of-use label where legally available. Label carve-outs must be consistent with FDA requirements and cannot remove medically necessary information in a way that creates an unlawful or unsafe product label.

No settlement date or active litigation outcome should be inferred without a current docket review. The economically relevant issue is whether a settlement grants an authorized-generic arrangement, a delayed entry date, or market access subject to dosage-form restrictions.

How strong is the deferiprone patent estate?

The estate is stronger for formulation and product execution than for the active ingredient itself.

Estate component	Relative strength	Reason
Active ingredient	Low	Mature small-molecule technology
Standard immediate-release tablet	Low	Conventional excipient architecture is readily substituted
Pediatric liquid	Moderate	Stability, taste, preservative, and dosing claims can be specific
Taste-masked dosage form	Moderate to high	Technical performance can support narrower but valuable claims
Modified-release product	Potentially high	Requires clinical and pharmacokinetic differentiation
Manufacturing process	Moderate	Impurity and scale-up controls can be difficult to replicate
Packaging and administration system	Moderate	Supports product differentiation but may be easy to design around

The best defensive strategy combines several narrower rights: formulation, manufacturing process, container closure, dosing device, and clinical-use positioning. A single broad excipient patent is less durable.

What are the commercial opportunities for deferiprone?

Generic tablets

Generic tablets are the lowest-risk entry opportunity. Competition will depend on price, supply continuity, tablet strengths, and regional procurement. A 1,000 mg tablet can reduce pill burden but may face greater swallowability constraints. A 500 mg tablet offers dose flexibility and may be preferred for pediatric or titration use.

Pediatric liquid

The oral-liquid segment has greater differentiation potential. A product with better taste, reliable dosing, and room-temperature stability could command a premium over a basic generic. Commercial success depends on specialist prescribing, reimbursement, caregiver preference, and procurement access.

Specialty and emerging markets

Thalassemia prevalence is concentrated in regions including the Mediterranean, Middle East, South Asia, and parts of Southeast Asia. Commercial opportunities include:

• Affordable generic tablets
• Government and hospital tenders
• Pediatric liquid products
• Local contract manufacturing
• Dual-language packaging
• Temperature-resilient supply chains
• Unit-dose packaging for community care

Market access may be more important than patent protection. Registration requirements, pharmacovigilance obligations, import controls, and tender qualification can delay entry after legal exclusivity ends.

Licensing and co-development

Licensing targets may include:

• Regional rights to generic deferiprone
• Pediatric formulations
• Taste-masking platforms
• Oral-syringe or unit-dose packaging
• Combination chelation products
• Contract manufacturing in high-prevalence markets

A formulation license is most attractive when it includes validated stability data, a scalable process, regulatory documentation, and freedom-to-operate analysis. A bare excipient patent without clinical usability evidence has limited negotiating value.

How does deferiprone compare with deferasirox and deferoxamine?

Attribute	Deferiprone	Deferasirox	Deferoxamine
Administration	Oral	Oral	Usually parenteral infusion
Formulation opportunity	Liquid, taste masking, tablets	Tablets, dispersible forms, oral granules	Infusion devices and reconstitution
Pediatric usability	Liquid and dose flexibility are important	Granules and tablets support differentiation	Administration burden remains high
Generic competition	Mature	Mature in many markets	Mature but technically complex
Key adherence issue	Multiple daily dosing and taste	Long-term oral tolerability and dosing	Infusion burden
Main safety-monitoring issue	Neutropenia/agranulocytosis	Renal, hepatic, and other monitoring	Ocular, auditory, and infusion-related risks

Deferiprone can compete through oral availability, iron-chelation efficacy in appropriate patients, and liquid dosing. It faces commercial pressure from once-daily oral alternatives, so dosing convenience and patient acceptability are important formulation levers.[3]

What generic launch risks exist for deferiprone?

A generic launch strategy should address four risks:

1. Regulatory risk from differences in inactive ingredients, especially for oral liquids.
2. Supply risk from specialized raw materials, packaging, or low-volume manufacturing.
3. Litigation risk involving listed formulation or method-of-use patents.
4. Commercial risk from limited market size and specialist prescribing.

The highest-probability launch path is a conventional immediate-release tablet with a well-controlled excipient profile. The highest-upside path is a pediatric liquid or taste-masked product, but it requires greater development, stability, palatability, and regulatory investment.

Key Takeaways

• Deferiprone is a mature small-molecule chelator with limited value in basic active-ingredient patenting.
• Excipient opportunities are strongest in taste masking, pediatric liquids, dose flexibility, stability, and packaging.
• The boxed warning for neutropenia and agranulocytosis limits safety-related formulation claims.
• Standard tablets are likely to compete primarily on price, supply reliability, and strength availability.
• Pediatric oral liquids can support premium positioning if they improve palatability, dosing accuracy, and in-use stability.
• Formulation patents should claim measurable technical effects, not routine excipient substitution.
• Generic entrants must review the current Orange Book, FDA exclusivity data, listed patents, and ANDA litigation status.
• The most defensible commercial strategy combines formulation rights, manufacturing controls, packaging differentiation, and regional market access.

FAQs About Deferiprone Formulation and Commercialization

Can deferiprone be developed as a chewable tablet?

Yes. A chewable product could address swallowing difficulty and reduce reliance on an oral solution. The main development issues are bitterness, dose uniformity, tablet mass, dental exposure, and pediatric acceptability.

Are taste-masking excipients likely to support a deferiprone patent?

They can, if the formulation produces a measurable improvement in taste, stability, dissolution, or administration. A routine flavor substitution is less likely to support durable patent protection.

Does deferiprone have biosimilar competition?

No. Deferiprone is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than biosimilar pathways.

Could a once-daily deferiprone product create a new market?

Potentially, but a once-daily product would require evidence supporting exposure, efficacy, safety, and adherence. Modified release would also create a higher regulatory and clinical-development burden.

Which deferiprone product has the strongest commercial differentiation potential?

A stable, palatable pediatric oral liquid with accurate dosing and convenient packaging has greater differentiation potential than a conventional immediate-release tablet.

References

1. U.S. Food and Drug Administration. (2024). Ferriprox (deferiprone) prescribing information. Chiesi USA, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2022). Deferiprone clinical pharmacology and prescribing information materials. https://www.fda.gov/drugs.